Official Title
Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment
Brief Summary

The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib. The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use. Named Patient Use (NPU)

Approved for marketing
Carcinoma, Non-Small-Cell Lung

Drug: BIBW 2992

tablets

Eligibility Criteria

Inclusion criteria:

- Patients with pathologic confirmation of adenocarcinoma of the lung Stage IIIB with
pleural effusion or Stage IV

Exclusion criteria:

- Brain metastases which are symptomatic; patients with treated, asymptomatic brain
metastases are eligible with stable brain disease for at least four 4 weeks without
the requirement for steroids or anti epileptic therapy

- Significant or recent acute gastrointestinal disorders with diarrhea as a major
symptom as judged by the investigator.

- Patients who have any other life-threatening illness or organ system dysfunction,
which in the opinion of the investigator, would either compromise patient safety or
interfere with the evaluation of the safety of the test drug

- History of cardiac disease that is clinically significant, as judged by the
investigator or uncontrolled cardiac disease (including congestive heart failure,
angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA)
functional classification of 3)

- Cardiac left ventricular function with resting ejection fraction of less than 50%

- Bilirubin 1.5 mg / dl (26 mol / L, SI unit equivalent)

- Aspartate amino transferase (AST) or alanine amino transferase (ALT) three times the
upper limit of normal (if related to liver metastases five times the upper limit of
normal)

- Serum creatinine 1.5 times of the upper normal limit or calculated/measured creatine
clearance 45ml/min

- Women of child-bearing potential or men who are able to father a child unwilling to
use a medically acceptable method of contraception during the trial

- Pregnancy or breast feeding

- Patients unable to comply with the protocol

- Patients with known HIV, active hepatitis B or active hepatitis C

- Pre-existing Interstitial Lung Disease (ILD)

- Requirement for treatment with any of the prohibited concomitant medications listed in
Section 4.2.2.1.

- Patients already pre-treated with BIBW 2992

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Australia
Locations

1200.47.1 Boehringer Ingelheim Investigational Site
North Ryde, New South Wales, Australia

Boehringer Ingelheim, Study Chair
Boehringer Ingelheim

Boehringer Ingelheim
NCT Number
MeSH Terms
Carcinoma, Non-Small-Cell Lung
Afatinib